ArticleCancer discovery2020
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02564900 (Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors), which is not on this map. Cited by 203 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors
Who cites it
203 citing papers in PubMed, 13 syntheses or guidelines pooled it, 345 citations in OpenAlex.
- The therapeutic potential of antibody-drug conjugates in advanced colorectal cancer: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Immunoconjugates in cervical cancer: a bibliometric and thematic mapping analysis of global research trends, 2015-2024.Frontiers in oncology · 2026Pooled it
- Comparative efficacy of trastuzumab deruxtecan versus guideline-recommended treatments for 2L+ unresectable locally advanced or metastatic HER2-mutant non-small cell lung cancer: a systematic review and indirect treatment comparison.Frontiers in oncology · 2025Pooled it
- A Systematic Review of Mechanisms, Incidence, and Management of Trastuzumab Deruxtecan Induced ILD/Pneumonitis in Solid Tumors.Drug design, development and therapy · 2025Pooled it
- Influence of antibody-drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: A systematic review and meta-analysis.Cancer metastasis reviews · 2024Pooled it
- How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer.Future oncology (London, England) · 2024Pooled it
- Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Analysis of Clinical Trials Using Anti-Tumor Traditional Chinese Medicine Monomers.Drug design, development and therapy · 2024Pooled it
- Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC).Current oncology (Toronto, Ont.) · 2023Pooled it
- Pooled it
- Safety of trastuzumab deruxtecan: A meta-analysis and pharmacovigilance study.Journal of clinical pharmacy and therapeutics · 2022Pooled it
- Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis.British journal of clinical pharmacology · 2022Pooled it
- Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.Cancer medicine · 2023Trial
- Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.BMC cancer · 2022Trial
- Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.JCO precision oncology · 2022Trial
- Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.BMC medicine · 2022Trial
- Trastuzumab Deruxtecan inThe New England journal of medicine · 2022Trial
143 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 12 institutions in 3 countries.
Funding
Abstract
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastric or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.